Sarah Prichard
Baxter International
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sarah Prichard.
BMC Nephrology | 2015
Frank Xiaoqing Liu; Peter Rutherford; Karen Smoyer-Tomic; Sarah Prichard; Suzanne Laplante
BackgroundPatient registries have great potential for providing data that describe disease burden, treatments, and outcomes; which can be used to improve patient care. Many renal registries exist, but a central repository of their scope, quality, and accessibility is lacking. The objective of this study was to identify and assess worldwide renal registries reporting on renal replacement therapy and compile a list of those most suitable for use by a broad range of researchers.MethodsRenal registries were identified through a systematic literature review and internet research. Inclusion criteria included information on dialysis use (yes/no), patient counts ≥300, and evidence of activity between June 2007 and June 2012. Public availability of information on dialysis modality, outcomes, and patient characteristics as well as accessibility of patient-level data for external research were evaluated.ResultsOf 144 identified renal registries, 48 met inclusion criteria, 23 of which were from Europe. Public accessibility to annual reports, publications, or basic data was good for 17 registries and moderate for 22. Patient-level data were available to external researchers either directly or through application and review (which may include usage fees) for 13 of the 48 registries, and were inaccessible or accessibility was unknown for 25.ConclusionsThe lack of available data, particularly in emerging economies, leaves information gaps about health care and outcomes for patients with renal disease. Effective multistakeholder collaborations could help to develop renal registries where they are absent, or enhance data collection and dissemination for currently existing registries to improve patient care.
Peritoneal Dialysis International | 2016
Jeffrey Perl; Simon J. Davies; Mark Lambie; Ronald L. Pisoni; Keith P. McCullough; David W. Johnson; James A. Sloand; Sarah Prichard; Hideki Kawanishi; Francesca Tentori; Bruce M. Robinson
♦ Background: Extending technique survival on peritoneal dialysis (PD) remains a major challenge in optimizing outcomes for PD patients while increasing PD utilization. The primary objective of the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) is to identify modifiable practices associated with improvements in PD technique and patient survival. In collaboration with the International Society for Peritoneal Dialysis (ISPD), PDOPPS seeks to standardize PD-related data definitions and provide a forum for effective international collaborative clinical research in PD. ♦ Methods: The PDOPPS is an international prospective cohort study in Australia, Canada, Japan, the United Kingdom (UK), and the United States (US). Each country is enrolling a random sample of incident and prevalent patients from national samples of 20 to 80 sites with at least 20 patients on PD. Enrolled patients will be followed over an initial 3-year study period. Demographic, comorbidity, and treatment-related variables, and patient-reported data, will be collected over the study course. The primary outcome will be all-cause PD technique failure or death; other outcomes will include cause-specific technique failure, hospitalizations, and patient-reported outcomes. ♦ Results: A high proportion of the targeted number of study sites has been recruited to date in each country. Several ancillary studies have been funded with high momentum toward expansion to new countries and additional participation. ♦ Conclusion: The PDOPPS is the first large, international study to follow PD patients longitudinally to capture clinical practice. With data collected, the study will serve as an invaluable resource and research platform for the international PD community, and provide a means to understand variation in PD practices and outcomes, to identify optimal practices, and to ultimately improve outcomes for PD patients.
Peritoneal Dialysis International | 2011
Ira Davis; Borut Cizman; Kelly Mundt; LieLing Wu; Robert W. Childers; Rod Mell; Sarah Prichard
♦ Background: To better understand the spectrum of overfill reports and their corresponding clinical severity and etiology, we conducted a review of overfill reports from the Manufacturer and User Facility Device Experience (MAUDE) database, which is within the Food and Drug Administration (FDA) Web site (www.fda.gov). ♦ Method: We searched the MAUDE database for events related to overfill reports between 1 January 1995 and 31 December 2008 and recorded drain volume (DV)/fill volume (FV), or DV/FV, and clinical symptoms and signs associated with the overfill report. ♦ Results: Among 462 MAUDE reports with a possible overfill event, 440 reports (95.2%) with a confirmed overfill event contained sufficient information to ascertain the clinical severity of the event. The number of reports with a clinical severity rating of minor, moderate, major, or death was 331, 71, 28, and 10, respectively. The median (range) DV/FV for a subgroup of 292 reports with a clinical severity rating of minor, moderate, major, or death was 1.63 (1.06 – 4.29), 1.71 (1.08 – 5.87), 2.14(1.64 – 2.61), and 2.50 (2.28 – 3.33), respectively. Insufficient drain accounted for a majority of overfill reports. ♦ Conclusion: Our analysis of reports from the MAUDE database suggests an association between DV/FV and clinical severity of the reported overfill event, as well as significant patient-to-patient variability with respect to intraperitoneal volume tolerance.
Archive | 1994
Sarah Prichard; Joanne M. Bargman
Peritoneal dialysis (PD) is now widely and successfully used to treat end-stage renal disease (ESRD) patients. The continuous nature of the therapy and its home-based, self-care nature make it particularly advantageous for certain subgroups of patients. Using the peritoneal cavity as access provides additional uses of the therapy in both uraemic and nonuraemic states. This chapter focuses on the use of PD in special groups of ESRD patients and in a variety of non-uraemic conditions.
Peritoneal Dialysis International | 1988
Sandra Donnelly; Mortimer Levy; Sarah Prichard
Peritoneal Dialysis International | 1999
Linda Fried; Alastair J. Hutchison; Bernd Stegmayr; Sarah Prichard; Joanne M. Bargman
Archive | 2009
Ying-Cheng Lo; Alp Akonur; Sarah Prichard
Peritoneal Dialysis International | 1999
Sarah Prichard
Archive | 2015
Frank Xiaoqing Liu; Peter Rutherford; Karen Smoyer-Tomic; Sarah Prichard; Suzanne Laplante
Nephrology Secrets (Third Edition) | 2012
James A. Sloand; Sarah Prichard